Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLARE: Erlotinib + Chemotherapy in EGFR-mutant NSCLC
NCT02178397Phase 3Terminated
- Sponsor
- Centre François Baclesse
- Start
- Jun 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Centre François Baclesse. Started Jun 2014; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02178397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178397.